Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    

 SummaryChartsNewsCalendarCompanyFinancialsRevisions 
Financials ($)
More Financials
Company
ImmunoCellular Therapeutics, Ltd. is a clinical-stage company, which engages in the development of immune-based therapies for the treatment of cancers.Its lead product candidate, ICT-107, is a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
05/23 IMMUNOCELLULAR THERAPEUTICS : The Law Offices of Howard G. Smith Notifies Invest..
05/20 IMMUNOCELLULAR THERAPEUTICS LTD : Lundin Law PC Announces a Securities Class Act..
05/18 IMMUNOCELLULAR THERAPEUTICS LTD : Khang & Khang LLP Announces a Securities Class..
05/18 Lundin Law PC Announces a Securities Class Action Lawsuit against ImmunoCellu..
05/18 IMMUNOCELLULAR THERAPEUTICS LTD : Levi & Korsinsky, LLP Notifies Shareholders of..
05/17 IMMUNOCELLULAR THERAPEUTICS LTD : Lundin Law PC Announces a Securities Class Act..
05/17 IMMUNOCELLULAR THERAPEUTICS LTD : IMUC The Law Offices of Vincent Wong Notifies ..
05/17 IMMUNOCELLULAR ALERT : Faruqi & Faruqi, LLP Encourages Investors Who Suffered Lo..
05/16 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
05/16 IMMUNOCELLULAR THERAPEUTICS, LTD. (N : IMUC) Files An 8-K Results of Operations ..
More news
Sector news : Biotechnology & Medical Research - NEC
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Ea..
2016 ImmunoCellular Therapeutics EPS in-line
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
2016 ImmunoCellular Therapeutics beats by $0.01
2016 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
Advertisement
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | US4525361055 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Anthony J. Gringeri President, Chief Executive Officer & Director
Gary S. Titus Chairman & Secretary
David E. Fractor Chief Financial Officer
John S. Yu Director
Rahul Singhvi Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPE..797.83%4
INCYTE CORPORATION35.79%27 528
QUINTILES IMS HOLDINGS..9.85%18 382
LONZA GROUP AG18.67%15 234
CELLTRION, INC.--.--%10 254
SEATTLE GENETICS, INC.26.04%9 492
More Results